Holen Sie sich die Stockscreener-App
76.56
0.09%
0.07
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt EW?
Forum
Prognose
Aktiensplit
Edwards Lifesciences Corp Aktie (EW) Neueste Nachrichten
Heart Valve Devices Market is projected to grow US$ 34.6 billion - openPR.com
Curious about Edwards Lifesciences (EW) Q2 Performance? Explore Wall Street Estimates for Key Metrics - Yahoo Finance
Earnings Preview: What To Expect From Edwards Lifesciences' Report - MSN
Lobbying Update: $360,000 of EDWARDS LIFESCIENCES LLC lobbying was just disclosed - Nasdaq
Edwards Lifesciences to Announce Q2 2025 Results, Driving Growth in Structural Heart Innovations - AInvest
What drives Edwards Lifesciences Corporation stock priceHigh-yield growth strategies - jammulinksnews.com
Edwards Lifesciences to Host Earnings Conference Call on July 24, 2025 - Yahoo Finance
Morgan Stanley Adjusts Price Target on Edwards Lifesciences to $81 From $75, Maintains Equalweight Rating - MarketScreener
Edwards Lifesciences Seeks to Add to its Irvine Campus - Orange County Business Journal
Edwards Lifesciences’ PROGRESS Trial: A Game-Changer for Aortic Stenosis Treatment? - TipRanks
Edwards Lifesciences Launches MITRIS Valve Study in China: A Potential Market Game-Changer - TipRanks
Argus Initiates Edwards Lifesciences at Buy, $90 Price Target - MarketScreener
Edwards Lifesciences’ SAPIEN X4 Valve Study: A Potential Game-Changer in Heart Valve Treatment - TipRanks
Edwards Lifesciences’ PASCAL System: A Promising Solution for Tricuspid Regurgitation - TipRanks
Edwards Lifesciences’ Pivotal Trial: A Game Changer in Tricuspid Valve Repair? - TipRanks
Edwards Lifesciences stock rating maintained at Hold by Canaccord Genuity - Investing.com Canada
Edwards Lifesciences’ PASCAL System: A Key Study Update for Investors - TipRanks
Edwards Lifesciences’ PASCAL System: A Promising Trial in Heart Valve Repair - TipRanks
Edwards Lifesciences Corporation(NYSE: EW) dropped from Russell 1000 Growth Index - MarketScreener
Edwards Lifesciences’ PASCAL System Trial: A Potential Game-Changer for Tricuspid Valve Repair - TipRanks
Edwards Lifesciences’ ALT-FLOW II Trial: A Potential Game-Changer in Heart Failure Treatment - TipRanks
Edwards Lifesciences’ MiCLASP Study: A Key Update for Investors - TipRanks
Edwards Lifesciences’ Cardioband FIT Study: A Potential Game-Changer in Valve Repair - TipRanks
EDWARDS' EVOQUE TRANSCATHETER TRICUSPID VALVE REPLACEMENT SYSTEM EARNS APPROVAL IN CANADA - BioSpace
Edwards Lifesciences Corp. v. Cardiovalve Ltd. (Fed. Cir. 2025) - JD Supra
Edwards Lifesciences’ Quarterly Earnings Preview: What You Need to Know - MSN
Court sides with Cardiovalve in Edwards patent spat - MassDevice
Edwards Can't Get Fed. Circ. To Overrule PTAB Amendments - Law360
Edwards Lifesciences Co. (NYSE:EW) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Is Edwards Lifesciences Stock Underperforming the Dow? - MSN
Is Edwards Lifesciences Stock Underperforming The Dow? - Barchart.com
Edwards Lifesciences CEO and CFO Set for Exclusive Fireside Chat at Major BofA Healthcare Conference - Stock Titan
Edwards Lifesciences: With A Heart Beating Strong And Steady (NYSE:EW) - Seeking Alpha
DBS Bank Adjusts Price Target on Edwards Lifesciences to $78 From $72, Maintains Hold Rating - MarketScreener
Leerink Partnrs Has Positive Estimate for EW Q3 Earnings - Defense World
Leerink Partners Adjusts PT on Edwards Lifesciences to $83 From $77, Maintains Market Perform Rating - marketscreener.com
Health Care Slips as Sector Continues to Lag Market -- Health Care Roundup - marketscreener.com
Edwards Lifesciences stock rises following competitor’s exit - Investing.com
Edwards Lifesciences’ SWOT analysis: stock poised for growth amid market expansion - Investing.com
Edwards' data shows benefits of early intervention in aortic stenosis - BioWorld MedTech
Edwards’ study demonstrates value in early aortic stenosis intervention - Yahoo Finance
Edwards' New Late-Breaking Data on Severe AS Expected to Boost Stock - Yahoo Finance
Assessing Edwards Lifesciences: Insights From 6 Financial Analysts - Benzinga
Edwards Lifesciences (EW) Receives Price Target Increase from Ci - GuruFocus
Edwards Lifesciences (EW) Receives Price Target Increase from Citigroup | EW Stock News - GuruFocus
Edwards highlights cost savings, improved outcomes with prompt intervention for aortic stenosis - MassDevice
Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes - marketscreener.com
Citigroup Adjusts Price Target on Edwards Lifesciences to $95 From $84, Maintains Buy Rating - marketscreener.com
Citi Raises Price Target for Edwards Lifesciences (EW) to $95 | - GuruFocus
Analyst Elevates Edwards Lifesciences (EW) as Top Pick | EW Stoc - GuruFocus
Citi Raises Price Target for Edwards Lifesciences (EW) to $95 | EW Stock News - GuruFocus
Citi adds Edwards Lifesciences stock as Top Pick, drops Insulet - Investing.com
Edwards Lifesciences Holds 2025 EPS Outlook Despite Tariff Headwind - insights.citeline.com
Jim Cramer Notes Edwards Lifesciences (EW) is in a “Good Zone” - Insider Monkey
2.37%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):